Journal Mobile Options
Table of Contents
Vol. 20, No. 6, 2005
Issue release date: November 2005
Section title: Original Research Article
Dement Geriatr Cogn Disord 2005;20:338–344

Donepezil in Vascular Dementia: Combined Analysis of Two Large-Scale Clinical Trials

Román G.C.a · Wilkinson D.G.e · Doody R.S.b · Black S.E.f · Salloway S.P.c · Schindler R.J.d
aDepartment of Medicine (Neurology), University of Texas Health Science Center and Audie Murphy Veterans Hospital, San Antonio, Tex., bDepartment of Neurology, Baylor College of Medicine, Houston, Tex., cClinical Neuroscience, Brown Medical School, Providence, R.I., and dPfizer Inc., New York, N.Y., USA; eMemory Assessment and Research Center, Moorgreen Hospital, Southampton, UK; fDepartment of Medicine (Neurology), Sunnybrook and Women’s College Health Sciences Centre, University of Toronto, Toronto, Canada
email Corresponding Author

Gustavo C. Román, MD

University of Texas Health Science Center, School of Medicine at San Antonio

Department of Medicine, Division of Neurology, Mail Code 7883, 7703 Floyd Curl Drive

San Antonio, TX 78229-3900 (USA)

Tel. +1 210 617 5161, Fax +1 210 567 4659, E-Mail


  1. Román GC: Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention. Med Clin North Am 2002;86:477–499.
  2. Looi JC, Sachdev PS: Differentiation of vascular dementia from AD on neuropsychological tests. Neurology 1999;53:670–678.
  3. Boyle PA, Cohen RA, Paul R, Moser D, Gordon N: Cognitive and motor impairments predict functional declines in patients with vascular dementia. Int J Geriatr Psychiatry 2002;17:164–169.
  4. Desmond DW, Moroney JT, Sano M, Stern Y: Mortality in patients with dementia after ischemic stroke. Neurology 2002;59:537–543.
  5. Johannsen P: Long-term cholinesterase inhibitor treatment of Alzheimer’s disease. CNS Drugs 2004;18:757–768.
  6. Lanctot KL, Herrmann N, Yau KK, Khan LR, Liu BA, Lou Lou MM, Einarson TR: Efficacy and safety of cholinesterase inhibitors in Alzheimer’s disease: a meta-analysis. CMAJ 2003;169:557–564.
  7. Swartz RH, Sahlas DJ, Black SE: Strategic involvement of cholinergic pathways and executive dysfunction: does location of white matter signal hyperintensity matter? J Stroke Cerebrovasc Dis 2003;12:29–36.
    External Resources
  8. Mesulam M, Siddique T, Cohen B: Cholinergic denervation in a pure multi-infarct state: observations on CADASIL. Neurology 2003;60:1183–1185.
  9. Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, Pratt RD, Donepezil 308 Study Group: Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003;61:479–486.
  10. Black S, Román GC, Geldmacher DS, Salloway S, Hecker J, Burns A, Perdomo C, Kumar D, Pratt R, Donepezil 307 Vascular Dementia Study Group: Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003;34:2323–2330.
  11. Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, et al: Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250–260.
  12. World Medical Association Declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997;277:925–926.
  13. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984;141:1356–1364.
  14. Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  15. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH: Validity and reliability of the Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11 (suppl 2):S22–S32.
    External Resources
  16. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL: A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566–572.
  17. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD, the ‘312’ Study Group: A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology2001;57:481–488.
  18. Cohen J: Statistical Power Calculations for the Behavioural Sciences, ed 2. Hillsdale, Lawrence Erlbaum Associates, 1988.
  19. Bender R: Number needed to treat (NNT); in Armitage P, Colton T (eds): Encyclopedia of Biostatistics, ed 2. Chichester, Wiley, 2004.
  20. Pratt RD: Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia. J Neurol Sci 2002;203–204:57–65.
  21. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV: Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet2002;359:1283–1290.
  22. Kittner B, De Deyn PP, Erkinjuntti T: Investigating the natural course and treatment of vascular dementia and Alzheimer’s disease: parallel study populations in two randomized, placebo-controlled trials. Ann NY Acad Sci 2000;903:535–541.
  23. Bowler JV, Eliasziw M, Steenhuis R, Munoz DG, Fry R, Merskey H, Hachinski VC: Comparative evolution of Alzheimer disease, vascular dementia, and mixed dementia. Arch Neurol1997;54:697–703.
  24. Wilcock G, Mobius HJ, Stoffler A: A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002;17:297–305.
  25. Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F: Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002;33:1834–1839.
  26. Rockwood K: Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2004;75:677–685.